{
    "ticker": "BBSC",
    "name": "Bluebird Bio, Inc.",
    "description": "Bluebird Bio, Inc. is a biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. Founded in 2010 and headquartered in Cambridge, Massachusetts, Bluebird Bio has pioneered the use of lentiviral gene therapy to address genetic disorders such as beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy. The company's innovative approach utilizes genetically modified cells to restore normal function, aiming to provide patients with life-altering treatments. Bluebird Bio's lead product candidates include LentiGlobin for beta-thalassemia and sickle cell disease, as well as Lenti-D for cerebral adrenoleukodystrophy. The company is also exploring applications of its technology in the field of oncology, targeting various blood cancers. With a strong commitment to research and development, Bluebird Bio collaborates with leading academic institutions and industry partners to advance its gene therapy programs. The company's mission is to unlock the potential of gene therapy to provide durable and curative treatments for patients facing serious conditions, ultimately improving their quality of life and health outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.bluebirdbio.com",
    "ceo": "Andrew Obenshain",
    "social_media": {
        "twitter": "https://twitter.com/bluebirdbio",
        "linkedin": "https://www.linkedin.com/company/bluebirdbio"
    },
    "investor_relations": "https://investors.bluebirdbio.com",
    "key_executives": [
        {
            "name": "Andrew Obenshain",
            "position": "CEO"
        },
        {
            "name": "Nick Leschly",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "LentiGlobin",
                "Lenti-D"
            ]
        }
    ],
    "seo": {
        "meta_title": "Bluebird Bio, Inc. | Transformative Gene Therapies",
        "meta_description": "Explore Bluebird Bio, Inc., a leader in gene therapy focused on severe genetic diseases and cancer. Learn about our innovative treatments and mission to improve patient lives.",
        "keywords": [
            "Bluebird Bio",
            "Gene Therapy",
            "Biotechnology",
            "Sickle Cell Disease",
            "Beta-Thalassemia",
            "LentiGlobin",
            "Lenti-D"
        ]
    },
    "faq": [
        {
            "question": "What does Bluebird Bio specialize in?",
            "answer": "Bluebird Bio specializes in developing gene therapies for severe genetic diseases and cancer."
        },
        {
            "question": "Who is the CEO of Bluebird Bio?",
            "answer": "Andrew Obenshain is the CEO of Bluebird Bio, Inc."
        },
        {
            "question": "Where is Bluebird Bio headquartered?",
            "answer": "Bluebird Bio is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Bluebird Bio's main products?",
            "answer": "Bluebird Bio's main products include LentiGlobin for beta-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy."
        },
        {
            "question": "When was Bluebird Bio founded?",
            "answer": "Bluebird Bio was founded in 2010."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO",
        "NVS"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "BIIB"
    ]
}